Allos Therapeutics, Inc. (Westminst...
Allos Therapeutics, Inc. (Westminster, CO) reported preliminary rises of a Phase 3 clinical trial that evaluated the radiation sensitizer agent RSR13 (efaproxiral) in controls with brain metastases. The randomized, open-label trial listed 538 subjects and was designed to compare the safety and efficacy of whole brain radiation therapy (WBRT) combined with the physic to WBRT alone. In the mix with drugs ...
|